|
1
|
Global Burden of Disease Cancer
Collaboration, ; Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T,
Alizadeh-Navaei R, Allen C, Alsharif U, Alvis-Guzman N, Amini E, et
al: Global, Regional, and national cancer incidence, mortality,
years of life lost, years lived with disability, and
disability-adjusted life-years for 29 cancer groups, 1990 to 2016:
A Systematic analysis for the global burden of disease study. JAMA
Oncol. 4:1553–1568. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Argiris A, Karamouzis MV, Raben D and
Ferris RL: Head and neck cancer. Lancet. 371:1695–1709. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Carvalho AL, Nishimoto IN, Califano JA and
Kowalski LP: Trends in incidence and prognosis for head and neck
cancer in the United States: A site-specific analysis of the SEER
database. Int J Cancer. 114:806–816. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Guan J, Li Q, Zhang Y, Xiao N, Chen M,
Zhang Y, Li L and Chen L: A meta-analysis comparing cisplatin-based
to carboplatin-based chemotherapy in moderate to advanced squamous
cell carcinoma of head and neck (SCCHN). Oncotarget. 7:7110–7119.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nagasaka M, Zaki M, Issa M, Kim H, Abrams
J and Sukari A: Definitive chemoradiotherapy with carboplatin for
squamous cell carcinoma of the head and neck. Laryngoscope.
127:2260–2264. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gao Y and Liu D: The roles of excision
repair cross-complementation group 1 in objective response after
cisplatin-based concurrent chemoradiotherapy and survival in head
and neck cancers: A systematic review and meta-analysis. Oral
Oncol. 51:570–577. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mehmood RK: Review of Cisplatin and
oxaliplatin in current immunogenic and monoclonal antibody
treatments. Oncol Rev. 8:2562014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chvalova K, Brabec V and Kasparkova J:
Mechanism of the formation of DNA-protein cross-links by antitumor
cisplatin. Nucleic Acids Res. 35:1812–1821. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chung CH, Lee JW, Slebos RJ, Howard JD,
Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, et
al: A 3′-UTR KRAS-variant is associated with cisplatin resistance
in patients with recurrent and/or metastatic head and neck squamous
cell carcinoma. Ann Oncol. 25:2230–2236. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Damia G and Broggini M: Platinum
resistance in ovarian cancer: Role of DNA repair. Cancers (Basel).
11:E1192019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fadejeva I, Olschewski H and Hrzenjak A:
MicroRNAs as regulators of cisplatin-resistance in non-small cell
lung carcinomas. Oncotarget. 8:115754–115773. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lambert IH and Sorensen BH: Facilitating
the cellular accumulation of Pt-based chemotherapeutic drugs. Int J
Mol Sci. 19(pii): E22492018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Leonhardt K, Gebhardt R, Mossner J,
Lutsenko S and Huster D: Functional interactions of Cu-ATPase ATP7B
with cisplatin and the role of ATP7B in the resistance of cells to
the drug. J Biol Chem. 284:7793–7802. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Inesi G: Molecular features of copper
binding proteins involved in copper homeostasis. IUBMB Life.
69:211–217. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Roberts EA: Update on the diagnosis and
management of wilson disease. Curr Gastroenterol Rep. 20:562018.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Morisawa A, Okui T, Shimo T, Ibaragi S,
Okusha Y, Ono M, Nguyen TTH, Hassan NMM and Sasaki A: Ammonium
tetrathiomolybdate enhances the antitumor effects of cetuximab via
the suppression of osteoclastogenesis in head and neck squamous
carcinoma. Int J Oncol. 52:989–999. 2018.PubMed/NCBI
|
|
18
|
Mese H, Sasaki A, Alcalde RE, Nakayama S
and Matsumura T: Establishment and characterization of
cisplatin-resistant human epidermoid carcinoma cell line, A431
cell. Chemotherapy. 44:414–420. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mese H, Sasaki A, Nakayama S, Alcalde RE
and Matsumura T: The role of caspase family protease, caspase-3 on
cisplatin-induced apoptosis in cisplatin-resistant A431 cell line.
Cancer Chemother Pharmacol. 46:241–245. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chan N, Willis A, Kornhauser N, Ward MM,
Lee SB, Nackos E, Seo BR, Chuang E, Cigler T, Moore A, et al:
Influencing the tumor microenvironment: A phase II study of copper
depletion using tetrathiomolybdate in patients with breast cancer
at high risk for recurrence and in preclinical models of lung
metastases. Clin Cancer Res. 23:666–676. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chisholm CL, Wang H, Wong AH,
Vazquez-Ortiz G, Chen W, Xu X and Deng CX: Ammonium
tetrathiomolybdate treatment targets the copper transporter ATP7A
and enhances sensitivity of breast cancer to cisplatin. Oncotarget.
7:84439–84452. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Park SJ, Kim MJ, Kim YK, Kim SM, Park JY
and Myoung H: Combined cetuximab and genistein treatment shows
additive anti-cancer effect on oral squamous cell carcinoma. Cancer
Lett. 292:54–63. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ishida S, Lee J, Thiele DJ and Herskowitz
I: Uptake of the anticancer drug cisplatin mediated by the copper
transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA.
99:14298–14302. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu X, Duan L, Zhou B, Ma R, Zhou H and Liu
Z: Genetic polymorphism of copper transporter protein 1 is related
to platinum resistance in Chinese non-small cell lung carcinoma
patients. Clin Exp Pharmacol Physiol. 39:786–792. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim ES, Tang X, Peterson DR, Kilari D,
Chow CW, Fujimoto J, Kalhor N, Swisher SG, Stewart DJ, Wistuba II
and Siddik ZH: Copper transporter CTR1 expression and tissue
platinum concentration in non-small cell lung cancer. Lung Cancer.
85:88–93. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Molloy SA and Kaplan JH: Copper-dependent
recycling of hCTR1, the human high affinity copper transporter. J
Biol Chem. 284:29704–29713. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fang T, Chen W, Sheng Y, Yuan S, Tang Q,
Li G, Huang G, Su J, Zhang X, Zang J and Liu Y: Tetrathiomolybdate
induces dimerization of the metal-binding domain of ATPase and
inhibits platination of the protein. Nat Commun. 10:1862019.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim KK, Han A, Yano N, Ribeiro JR, Lokich
E, Singh RK and Moore RG: Tetrathiomolybdate mediates
cisplatin-induced p38 signaling and EGFR degradation and enhances
response to cisplatin therapy in gynecologic cancers. Sci Rep.
5:159112015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Okui T, Shimo T, Fukazawa T, Kurio N,
Hassan NM, Honami T, Takaoka M, Naomoto Y and Sasaki A: Antitumor
effect of temsirolimus against oral squamous cell carcinoma
associated with bone destruction. Mol Cancer Ther. 9:2960–2969.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kilari D, Guancial E and Kim ES: Role of
copper transporters in platinum resistance. World J Clin Oncol.
7:106–113. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fu S, Naing A, Fu C, Kuo MT and Kurzrock
R: Overcoming platinum resistance through the use of a
copper-lowering agent. Mol Cancer Ther. 11:1221–1225. 2012.
View Article : Google Scholar : PubMed/NCBI
|
